Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?

被引：1
|
作者：
Johnson, Gillian G. [1 ,2 ]
Carr, Daniel F. [3 ]
Pirmohamed, Munir [3 ]
Pettitt, Andrew R. [2 ]
机构：
[1] Royal Liverpool & Broadgreen Univ Hosp Trust, Dept Haematol, Liverpool, Merseyside, England
[2] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool L69 3BX, Merseyside, England
[3] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England
来源：
PHARMACOGENOMICS | 2014年 / 15卷 / 07期
基金：
英国医学研究理事会;
关键词：
adverse drug reactions; bendamustine; chronic lymphocytic leukemia; cyclophosphamide; fludarabine; personalized medicine; pharmacogenomics; GENETIC-POLYMORPHISM; UNTREATED PATIENTS; HUMAN LIVER; RITUXIMAB; CYCLOPHOSPHAMIDE; BENDAMUSTINE; CHLORAMBUCIL; FLUDARABINE; EXPRESSION; VARIANTS;
D O I：
10.2217/pgs.14.60
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：897 / 900
页数：4
相关论文
共 50 条
  • [21] Bendamustine in the treatment of chronic lymphocytic leukemia
    Knaulf, Wolfgang
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (02) : 165 - 174
  • [22] Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China
    Xu, Zhenshu
    Zhang, Jinyan
    Wu, Shunquan
    Zheng, Zhihong
    Chen, Zhizhe
    Zhan, Rong
    ONCOLOGY LETTERS, 2013, 5 (04) : 1266 - 1272
  • [23] Slaying the real giants in the war on chronic lymphocytic leukemia Comment
    Cheson, Bruce D.
    CHINESE CLINICAL ONCOLOGY, 2022, 11 (05)
  • [24] Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options
    Sharma, Sandhya
    Rai, Kanti R.
    CANCER, 2019, 125 (09) : 1432 - 1440
  • [25] Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995-2017
    Weide, Rudolf
    Feiten, Stefan
    Chakupurakal, Geothy
    Friesenhahn, Vera
    Kleboth, Kristina
    Koeppler, Hubert
    Lutschkin, Julia
    van Roye, Christoph
    Thomalla, Joerg
    Heymanns, Jochen
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 557 - 566
  • [26] Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis
    Hus, Iwona
    Jawniak, Dariusz
    Gorska-Kosicka, Magdalena
    Butrym, Aleksandra
    Dzietczenia, Justyna
    Wrobel, Tomasz
    Mazur, Grzegorz
    Lech-Maranda, Ewa
    Warzocha, Krzysztof
    Waszczuk-Gajda, Anna
    Jedrzejczak, W. Wiktor
    Krawczyk-Kulis, Malgorzata
    Kyrcz-Krzemien, Slawomira
    Poplawska, Lidia
    Walewski, Jan
    Dmoszynska, Anna
    CHEMOTHERAPY, 2013, 59 (04) : 280 - 289
  • [27] What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
    Cheson, Bruce D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (11): : 723 - 727
  • [28] Economic burden of treatment failure in chronic lymphocytic leukemia patients
    Wang, Song
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Romdhani, Hela
    Emond, Bruno
    Senbetta, Mekre
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 1135 - 1142
  • [29] Chronic Lymphocytic Leukemia Treatment Options for Patients With Refractory Disease
    Motta, Marina
    Wierda, William G.
    Ferrajoli, Alessandra
    CANCER, 2009, 115 (17) : 3830 - 3841
  • [30] Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial
    Molica, Stefano
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (09) : 1333 - 1340
12345